Institution of Chemical Engineers Discusses Process Safety - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Institution of Chemical Engineers Discusses Process Safety


The Institution of Chemical Engineers (IChemE) commented on a study, which found that one in five accidents caused by equipment failures in the chemical process industries are the result of human and organizational errors, and discussed the importance of process safety in a recent press release.

“Accidents caused by equipment failures have many potential causes including contamination, corrosion, poor installation, and mechanical failures. But it is worrying to see that human and organizational failures head the list of contributing factors,” said David Brown, chief executive of IChemE, in the press release. “Competence in process safety lies at the heart of the chemical engineering skill set. Hopefully, our work over the next few years to introduce a new international qualification for process safety professionals, the development of a virtual safety center, and our ambition to promote higher standards in the corporate governance of process safety will help drive down avoidable accidents,” added Brown.

IChemE is a global professional membership organization with offices in Australia, China, Malaysia, New Zealand, Singapore and the UK. Earlier this year, IChemE published a revised technical strategy document,Chemical Engineering Matters, which outlines IChemE’s broader thinking on the areas where the profession creates, maintains, or improves quality of life. One focus of the strategy is the role of chemical engineering in process safety. 

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
26%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
10%
All of the above.
43%
No government involvement in patient treatment or drug development.
10%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?

Click here